Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Apogee Therapeutics Inc. (APGE) had Consolidated Net Income/Loss of $-74.11M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-74.11M |
|
-- |
|
-- |
|
$82.77M |
|
$-82.77M |
|
$8.74M |
|
$-74.03M |
|
$-74.03M |
|
$-74.11M |
|
$-74.11M |
|
|
Consolidated Net Income/Loss |
$-74.11M |
$-74.11M |
|
$-82.77M |
|
$-83.91M |
|
69.67M |
|
69.67M |
|
$-1.06 |
|
$-1.06 |
|
| Balance Sheet Financials | |
$1.07B |
|
$5.28M |
|
$219.86M |
|
$1.29B |
|
$32.95M |
|
-- |
|
$4.91M |
|
$37.86M |
|
$1.26B |
|
$1.26B |
|
$1.26B |
|
74.88M |
|
| Cash Flow Statement Financials | |
$-55.57M |
|
$-35.35M |
|
$411.17M |
|
$131.55M |
|
$451.80M |
|
$320.25M |
|
$17.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
32.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-55.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.90% |
|
-5.90% |
|
-5.73% |
|
-5.90% |
|
$16.77 |
|
$-0.80 |
|
$-0.80 |
|